Literature DB >> 12673028

Antidepressant-like effects of apigenin and 2,4,5-trimethoxycinnamic acid from Perilla frutescens in the forced swimming test.

Takahiro Nakazawa1, Takaaki Yasuda, Joji Ueda, Keisuke Ohsawa.   

Abstract

We studied the effects of apigenin and 2,4,5-trimethoxycinnamic acid (TMCA) on the behavioral despair test (forced swimming test), and the central noradrenergic, dopaminergic and serotonergic activities in mice. Apigenin at intraperitoneal doses of 12.5 and 25 mg/kg significantly decreased the duration of immobility in the forced swimming test in mice. At 100 mg/kg, the duration of immobility was returned to the control level in the test. On the other hand, TMCA treatment (25-200 mg/kg, i.p.) failed to significantly alter the duration of immobility. Based on the behavioral data, we examined changes in the monoamine turnover in mice having been subjected to forced swimming for 40 min. The monoamine turnover was measured in seven brain regions. Forced swimming exposure induced a significant decrease in dihydroxyphenylacetic acid (DOPAC)/dopamine (DA) in the striatum and amygdala and in 5-hydroxyindoleacetic acid (5-HIAA)/5-hydroxytriptamine (5-HT) in the hypothalamus, and a significant increase in DOPAC/DA in the thalamus and hypothalamus and in 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG)/norepinephrine (NE) in the amygdala, frontal cortex, hypothalamus, and midbrain. Apigenin (25 mg/kg) treatment produced attenuation of forced swim test-induced decrease of DA turnover in the amygdala and increase of DA turnover in the hypothalamus. Furthermore, intraperitoneal administration of haloperidol (0.2 mg/kg), a dopamine D(2) antagonist, blocked the apigenin (25 mg/kg)-induced decrease in immobility in the forced swimming test. These behavioral and biochemical results indicate the antidepressant properties of apigenin, which may be mediated by the dopaminergic mechanisms in the mouse brain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673028     DOI: 10.1248/bpb.26.474

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  30 in total

Review 1.  Neuroprotection by spice-derived nutraceuticals: you are what you eat!

Authors:  Ramaswamy Kannappan; Subash Chandra Gupta; Ji Hye Kim; Simone Reuter; Bharat Bhushan Aggarwal
Journal:  Mol Neurobiol       Date:  2011-03-01       Impact factor: 5.590

Review 2.  Traditional Chinese medicine and Western psychopharmacology: building bridges.

Authors:  Edward Shorter; Kathryn Segesser
Journal:  Phytother Res       Date:  2013-02-17       Impact factor: 5.878

3.  Chamomile (Matricaria recutita) may provide antidepressant activity in anxious, depressed humans: an exploratory study.

Authors:  Jay D Amsterdam; Justine Shults; Irene Soeller; Jun James Mao; Kenneth Rockwell; Andrew B Newberg
Journal:  Altern Ther Health Med       Date:  2012 Sep-Oct       Impact factor: 1.305

4.  Putative Antidepressant Effect of Chamomile (Matricaria chamomilla L.) Oral Extract in Subjects with Comorbid Generalized Anxiety Disorder and Depression.

Authors:  Jay D Amsterdam; Qing S Li; Sharon X Xie; Jun J Mao
Journal:  J Altern Complement Med       Date:  2019-12-05       Impact factor: 2.579

5.  Alpha1,6-fucosyltransferase-deficient mice exhibit multiple behavioral abnormalities associated with a schizophrenia-like phenotype: importance of the balance between the dopamine and serotonin systems.

Authors:  Tomohiko Fukuda; Hirokazu Hashimoto; Natsumi Okayasu; Akihiko Kameyama; Hiroshi Onogi; Osamu Nakagawasai; Takahiro Nakazawa; Tomoyo Kurosawa; Yan Hao; Tomoya Isaji; Takeshi Tadano; Hisashi Narimatsu; Naoyuki Taniguchi; Jianguo Gu
Journal:  J Biol Chem       Date:  2011-04-06       Impact factor: 5.157

6.  Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder.

Authors:  John R Keefe; Jun J Mao; Irene Soeller; Qing S Li; Jay D Amsterdam
Journal:  Phytomedicine       Date:  2016-10-24       Impact factor: 5.340

7.  Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial.

Authors:  Jun J Mao; Sharon X Xie; John R Keefe; Irene Soeller; Qing S Li; Jay D Amsterdam
Journal:  Phytomedicine       Date:  2016-10-24       Impact factor: 5.340

8.  A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder.

Authors:  Jay D Amsterdam; Yimei Li; Irene Soeller; Kenneth Rockwell; Jun James Mao; Justine Shults
Journal:  J Clin Psychopharmacol       Date:  2009-08       Impact factor: 3.153

9.  Evaluation of potential antidepressant-like activity of chalcone-1203 in various murine experimental depressant models.

Authors:  Li-Ping Guan; Li-Ming Tang; Cheng-Yan Pan; Shui-Lian Zhao; Si-Hong Wang
Journal:  Neurochem Res       Date:  2013-12-17       Impact factor: 3.996

10.  The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.

Authors:  Judith A Siuciak; Remie A Fujiwara
Journal:  Psychopharmacology (Berl)       Date:  2004-02-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.